CF Foundation Affirms Support of the Introduction of the PASTEUR Act

Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.

| 2 min read

Today, the Cystic Fibrosis Foundation affirmed its support for the PASTEUR Act, a bipartisan proposal that, if passed, will support the development of new antibiotics and promote appropriate use of existing ones.

“New solutions are needed now to bring novel antibiotics into the hands of patients. The Cystic Fibrosis Foundation applauds Senators Bennet and Young in reintroducing the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act. If passed, the PASTEUR Act has the potential to spur vital investment into new antibiotics by addressing the economic disincentives that have long been associated with antibiotic development.

"Routine use of antibiotics in cystic fibrosis care is medically necessary but unfortunately, too many people with CF find themselves battling difficult-to treat infections where existing antibiotics are not effective. However, antibiotic resistance is not solely a CF problem-it's a human problem that we can no longer ignore. 

"People with CF need more antibiotic options as do all Americans. The Foundation is making significant investments into the research and development of new approaches to address infections, but more is needed. Congress must take swift action to pass the PASTEUR Act, invigorating a new era of antibiotic research and development that could bring novel treatments into the hands of patients who need them the most."

For more information about the Foundation's work in fighting antimicrobial resistance, visit cff.org.

About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, visit cff.org.

Media Contact
Ashley Mahoney
Email: amahoney@cff.org 
Phone: 240-200-3754

Share this article
Topics
Antibiotics | Advocacy
Recent news
Cystic Fibrosis Foundation Invests an Additional $5 Million in BiomX
News | 2 min read
Cystic Fibrosis Foundation Invests More Than $6.6 Million in Additional Funding in Sionna Therapeutics
News | 2 min read
Bruce Marshall, Chief Medical Officer, to Retire From the CF Foundation
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe